Tag - FHTX

H.C. Wainwright initiated coverage of Foghorn Therapeutics (NASDAQ:FHTX) with a “buy” rating and price target of $25. The stock closed at $13.68 on Nov. 19. Foghorn is a leader in the field of chromatin biology. The...